Is Egrifta (Tesamorelin) Legal in Arizona?

FDA Approval and Federal Legal Framework

Egrifta (tesamorelin) carries full FDA approval and is a Schedule-free prescription medication. The FDA first approved Egrifta on August 27, 2010, under NDA 022505, specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [1] A reformulated version, Egrifta SV (stable formulation), received FDA approval in 2019 and replaced the original product. [1]

Because tesamorelin is not listed under the Controlled Substances Act by the DEA, there is no federal scheduling restriction on prescribing or dispensing it. [2] This places it in the same legal category as other prescription-only biologics: legal to prescribe, dispense, and possess with a valid prescription, but illegal to distribute without one.

What the FDA Approval Covers

The approval covers a single indication: lipodystrophy-related visceral adiposity in adults with HIV. The prescribing information specifies a dose of 2 mg subcutaneously once daily, administered in the abdominal area. [3] The FDA label is explicit that Egrifta is not indicated for weight loss management in the general population or for anti-aging purposes. [3]

What "FDA-Approved" Means Legally

An FDA-approved drug may be prescribed off-label by a licensed clinician; that practice is legal under federal law and standard medical custom. The FDA does not restrict how physicians prescribe approved drugs once those drugs are on the market, though off-label marketing by manufacturers is prohibited. Off-label use of tesamorelin, such as for non-HIV visceral fat or cognitive endpoints, is therefore a legal prescribing decision in Arizona, even though it goes beyond the approved labeling. [4]

The NEJM-published Phase III trial (N=412) that supported the original FDA approval showed that tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 18% versus placebo at 26 weeks (P<0.001). [5] A subsequent maintenance trial (N=273) confirmed that continued therapy was required to sustain those reductions; visceral fat returned toward baseline within 26 weeks after discontinuation. [6]

Arizona State Law and Tesamorelin

Arizona adds no independent state-level prohibition on tesamorelin beyond what federal law already requires. Arizona law classifies prescription drugs under A.R.S. § 32-1901 and related statutes governing the Arizona State Board of Pharmacy. [7] Under that framework, a drug requiring a federal prescription also requires a valid Arizona prescription; there is no additional controlled-substance classification for tesamorelin at the state level.

Arizona Board of Pharmacy Rules

The Arizona State Board of Pharmacy regulates the dispensing, storage, and labeling of all prescription drugs within Arizona, including biologics like tesamorelin. [7] Licensed Arizona pharmacies, including state-licensed specialty pharmacies and mail-order pharmacies holding an Arizona permit, may dispense Egrifta SV when presented with a valid prescription. The Board's regulations do not single out tesamorelin for any heightened restriction beyond standard prescription-only requirements.

Arizona Medical Practice Act

The Arizona Medical Practice Act (A.R.S. § 32-1401 et seq.) governs physician prescribing. [8] Physicians licensed by the Arizona Medical Board may prescribe tesamorelin for any medically appropriate indication, including off-label uses, provided the prescription is grounded in a legitimate clinical evaluation. Nurse practitioners and physician assistants with appropriate prescriptive authority under Arizona law may also prescribe tesamorelin within their scope of practice. [8]

Telemedicine Prescribing in Arizona

Arizona's telemedicine statute (A.R.S. § 36-3601 et seq.) permits prescribing via telemedicine when the prescriber has established a valid patient-provider relationship and meets standard-of-care requirements. [9] This means an Arizona-licensed telehealth provider can legally prescribe Egrifta or discuss tesamorelin therapy without an in-person visit, as long as the clinical evaluation is thorough and documented. The Arizona Telemedicine Program at the University of Arizona has published guidance confirming that telemedicine prescribing follows the same legal standards as in-person prescribing. [9]

Compounded Tesamorelin: A More Complex Picture

Compounded tesamorelin occupies a different regulatory space from brand-name Egrifta SV. The rules here are set primarily by the FDA and the federal Drug Quality and Security Act (DQSA) of 2013, not by Arizona alone.

503A Compounding Pharmacies

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may prepare a drug for an individual patient based on a valid prescription. [10] However, FDA policy generally restricts 503A pharmacies from compounding copies of FDA-approved drugs that are commercially available. Because Egrifta SV is commercially available, a 503A pharmacy compounding tesamorelin in the same route of administration (subcutaneous injection) and the same dose faces a legal risk of FDA enforcement action. The FDA's guidance on this point has evolved since 2020, and practitioners should confirm current enforcement posture before relying on 503A-compounded tesamorelin. [10]

503B Outsourcing Facilities and the Bulks List

Section 503B outsourcing facilities can compound drugs from bulk active pharmaceutical ingredients (APIs) without individual prescriptions, but only if those APIs appear on the FDA's 503B Bulks List. [11] The FDA has, at various points, included or proposed tesamorelin-related substances for evaluation under that list. As of 2024, practitioners should verify the current Bulks List status directly on the FDA website before sourcing compounded tesamorelin from a 503B facility, because the list is updated on a rolling basis and enforcement actions have followed removals. [11]

The Practical Takeaway on Compounding

If you want tesamorelin legally and without regulatory ambiguity, brand-name Egrifta SV from a licensed pharmacy on a valid prescription is the clearest path. Compounded tesamorelin may be available, but the prescriber and patient both assume greater regulatory risk. Any Arizona provider recommending compounded tesamorelin should document the clinical rationale and verify that the compounding pharmacy holds current licensure from the Arizona Board of Pharmacy and, if a 503B facility, FDA registration. [7, 11]

The HealthRX clinical team uses a three-checkpoint framework before recommending any compounded peptide in Arizona: (1) confirm the API is on the current FDA 503B Bulks List or that a 503A patient-specific medical necessity exemption applies; (2) verify the compounding pharmacy's Arizona Board of Pharmacy license and, for 503B facilities, FDA registration; (3) document a specific clinical rationale in the chart that justifies the compounded route over a commercially available alternative.

Clinical Evidence Behind Tesamorelin

Understanding the evidence base matters legally and clinically. The FDA's approval was built on two randomized controlled trials published in peer-reviewed literature, meaning tesamorelin is not experimental for its approved indication.

Phase III Trial Data

The key trial published in NEJM enrolled 412 HIV-positive adults with abdominal lipodystrophy. Subjects receiving tesamorelin 2 mg/day showed an 18% reduction in visceral adipose tissue area by CT scan at 26 weeks versus a 2% reduction in the placebo group (P<0.001). [5] Triglyceride levels also dropped by a mean of 50 mg/dL in the treatment arm. [5]

A second randomized trial (N=273) tested a maintenance design: responders at 26 weeks were rerandomized to continue tesamorelin or switch to placebo. Those who continued active treatment maintained their visceral fat reduction, while those switched to placebo regained a mean 14% of lost visceral fat area within 26 weeks. [6] This finding shapes the clinical conversation about duration of therapy: tesamorelin is not a one-time course but requires ongoing dosing to sustain benefit.

Off-Label Research

Off-label interest in tesamorelin has grown around cognitive aging. A trial published in the Journal of Clinical Endocrinology and Metabolism (Baker et al., N=152, average age 65) showed that tesamorelin 1 mg/day for 20 weeks improved performance on the Modified Mini-Mental State Examination and reduced amyloid-beta accumulation compared with placebo. [12] This study does not change the legal status of the drug, but it illustrates why some non-HIV patients and prescribers request it.

A separate investigation by Falutz et al. Examined tesamorelin's effects on IGF-1, finding statistically significant elevations in IGF-1 levels among treated patients. [13] Because elevated IGF-1 is associated with certain cancer risks in observational data, the FDA label carries a contraindication for patients with active malignancies and a warning about IGF-1 monitoring. [3] Prescribers in Arizona must review these label warnings before initiating therapy.

How to Get Egrifta (Tesamorelin) in Arizona

Getting tesamorelin in Arizona legally requires a prescription from a licensed Arizona provider, dispensed through a licensed pharmacy. The steps below reflect current federal and state requirements.

Step 1: Establish Care With a Licensed Arizona Provider

The prescriber must hold an active Arizona license. For telehealth, the prescriber must comply with Arizona telemedicine statute A.R.S. § 36-3601. [9] Initial evaluation should include a clinical assessment of the indication, review of contraindications (active malignancy, pregnancy, pituitary disorders, hypersensitivity to tesamorelin or mannitol), and baseline IGF-1 measurement. [3]

Step 2: Obtain Lab Work

The FDA label recommends baseline IGF-1 levels and monitoring at regular intervals during therapy. [3] Fasting lipid panel and glucose measurements are standard given tesamorelin's effects on triglycerides and glucose metabolism. Arizona telehealth providers can order labs through national reference laboratories (LabCorp, Quest) with patient service centers throughout the state.

Step 3: Fill the Prescription at a Licensed Pharmacy

Egrifta SV is a specialty medication distributed through specialty pharmacy networks. Your prescriber's office or telehealth platform typically handles prior authorization if insurance coverage is sought. Without insurance, Ther-Rx/Theratechnologies (the manufacturer) operates a patient assistance program; contact information is on the Egrifta SV product page. [1] Arizona residents may also use mail-order specialty pharmacies holding a valid Arizona Board of Pharmacy out-of-state permit. [7]

Insurance and Cost Considerations

Egrifta SV is expensive without coverage, with retail costs exceeding $5,000 per month in some pharmacy benefit tiers. Insurance coverage is generally tied to the FDA-approved indication; coverage for off-label use varies substantially by plan. The manufacturer's website lists specialty pharmacy partners and co-pay assistance for eligible patients. [1] Off-label prescriptions for non-HIV patients will almost certainly require self-pay or a detailed prior-authorization appeal.

Contraindications and Safety Signals Relevant to Arizona Prescribers

Arizona prescribers operating under the state Medical Practice Act must meet the standard of care when prescribing tesamorelin. [8] The FDA label identifies the following absolute contraindications: disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor or surgery; active malignancy; pregnancy; and known hypersensitivity to tesamorelin or mannitol. [3]

The label also carries warnings about fluid retention (edema, arthralgias, carpal tunnel syndrome), glucose intolerance, and IGF-1 elevation. [3] The American Association of Clinical Endocrinology (AACE) guidelines on growth hormone-related therapy note that IGF-1 elevations above age-adjusted normal ranges warrant dose reduction or discontinuation. [14] Arizona prescribers should document IGF-1 monitoring at 3-month intervals and adjust dosing accordingly.

Injection-site reactions occurred in approximately 25% of patients in the Phase III trial, most rated mild to moderate. [5] Patients self-administering in Arizona should receive formal injection training, typically provided by the dispensing specialty pharmacy.

Peptide vs. Drug Classification: Why It Matters in Arizona

Tesamorelin is classified as a synthetic peptide and a drug, not a dietary supplement or a research chemical. This distinction matters because some growth hormone-releasing peptides circulate in gray markets as "research chemicals" with minimal oversight. Tesamorelin is not in that category. It has an NDA, a manufacturer, and an approved label. [1] Purchasing tesamorelin from a non-pharmacy source, such as a research chemical vendor, is illegal under the Federal Food, Drug, and Cosmetic Act, regardless of what state you live in. Arizona's Consumer Fraud Act (A.R.S. § 44-1521) could also apply to vendors misrepresenting such products. The only legal acquisition path is through a licensed prescriber and a licensed pharmacy.